- Home
- RPRX vs BIIB Comparison
RPRX vs BIIB Comparison
Compare RPRX & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- BIIB
- Stock Information
- Founded
- RPRX 1996
- BIIB 1978
- Country
- RPRX United States
- BIIB United States
- Employees
- RPRX N/A
- BIIB N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- RPRX Health Care
- BIIB Health Care
- Exchange
- RPRX Nasdaq
- BIIB Nasdaq
- Market Cap
- RPRX 16.2B
- BIIB 24.2B
- IPO Year
- RPRX 2020
- BIIB 1991
- Fundamental
- Price
- RPRX $39.23
- BIIB $168.52
- Analyst Decision
- RPRX Strong Buy
- BIIB Buy
- Analyst Count
- RPRX 3
- BIIB 24
- Target Price
- RPRX $46.00
- BIIB $174.62
- AVG Volume (30 Days)
- RPRX 3.9M
- BIIB 1.8M
- Earning Date
- RPRX 11-05-2025
- BIIB 10-30-2025
- Dividend Yield
- RPRX 2.25%
- BIIB N/A
- EPS Growth
- RPRX N/A
- BIIB N/A
- EPS
- RPRX 1.75
- BIIB 10.97
- Revenue
- RPRX $2,349,844,000.00
- BIIB $10,065,900,000.00
- Revenue This Year
- RPRX $36.16
- BIIB $2.97
- Revenue Next Year
- RPRX $2.04
- BIIB N/A
- P/E Ratio
- RPRX $22.36
- BIIB $15.27
- Revenue Growth
- RPRX 3.70
- BIIB 4.77
- 52 Week Low
- RPRX $24.05
- BIIB $110.04
- 52 Week High
- RPRX $41.24
- BIIB $175.86
- Technical
- Relative Strength Index (RSI)
- RPRX 59.26
- BIIB 74.64
- Support Level
- RPRX $38.39
- BIIB $151.83
- Resistance Level
- RPRX $40.01
- BIIB $157.79
- Average True Range (ATR)
- RPRX 1.26
- BIIB 5.59
- MACD
- RPRX 0.12
- BIIB 1.37
- Stochastic Oscillator
- RPRX 63.19
- BIIB 95.37
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).